JP2017533961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533961A5 JP2017533961A5 JP2017543288A JP2017543288A JP2017533961A5 JP 2017533961 A5 JP2017533961 A5 JP 2017533961A5 JP 2017543288 A JP2017543288 A JP 2017543288A JP 2017543288 A JP2017543288 A JP 2017543288A JP 2017533961 A5 JP2017533961 A5 JP 2017533961A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- bolus
- subject
- tpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 8
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 8
- 108010073863 saruplase Proteins 0.000 claims 6
- 208000006011 Stroke Diseases 0.000 claims 5
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 4
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 230000002537 thrombolytic effect Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 229920000742 Cotton Polymers 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074374P | 2014-11-03 | 2014-11-03 | |
| US62/074,374 | 2014-11-03 | ||
| PCT/US2015/058878 WO2016073514A2 (en) | 2014-11-03 | 2015-11-03 | Methods and compositions for safe and effective thrombolysis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533961A JP2017533961A (ja) | 2017-11-16 |
| JP2017533961A5 true JP2017533961A5 (enExample) | 2018-12-06 |
| JP6826040B2 JP6826040B2 (ja) | 2021-02-03 |
Family
ID=55910021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543288A Active JP6826040B2 (ja) | 2014-11-03 | 2015-11-03 | 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11213574B2 (enExample) |
| EP (2) | EP3708226A1 (enExample) |
| JP (1) | JP6826040B2 (enExample) |
| CN (1) | CN107073292B (enExample) |
| CA (1) | CA2966332C (enExample) |
| DK (1) | DK3215221T3 (enExample) |
| EA (1) | EA035358B1 (enExample) |
| ES (1) | ES2788697T3 (enExample) |
| MX (1) | MX383561B (enExample) |
| WO (1) | WO2016073514A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107073292B (zh) | 2014-11-03 | 2021-07-02 | 溶栓科学有限责任公司 | 用于安全和有效的溶栓的方法和组合物 |
| US11154596B2 (en) | 2017-06-16 | 2021-10-26 | Thrombolytic Science, Llc | Methods for thrombolysis |
| CN107516010B (zh) * | 2017-08-19 | 2021-02-09 | 上海矩点医疗科技有限公司 | 溶栓剂量模型的构建方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381346A (en) | 1979-11-13 | 1983-04-26 | Huasin Syed S | Isolation of plasminogen activators useful as therapeutic and diagnostic agents |
| GB8623823D0 (en) | 1986-10-03 | 1986-11-05 | Sandoz Ltd | Therapeutic lysis of fibrin blood clots |
| GB2197195B (en) | 1986-10-03 | 1991-01-23 | Sandoz Ltd | Improvments in or relating to organic compounds |
| US5108901A (en) | 1988-09-02 | 1992-04-28 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| GB8823833D0 (en) | 1988-10-11 | 1988-11-16 | Erba Carlo Spa | Production of human prourokinase |
| US5843089A (en) | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| JP3559559B2 (ja) * | 1992-06-03 | 2004-09-02 | ジェネンテク，インコーポレイテッド | 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体 |
| EP0682700A4 (en) | 1993-02-05 | 1997-05-28 | Vascular Lab | USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE. |
| US5472692A (en) | 1993-07-02 | 1995-12-05 | New England Deaconess Hospital Corporation | Pro-urokinase mutants |
| US5510330A (en) | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| US5810767A (en) | 1994-05-11 | 1998-09-22 | Localmed, Inc. | Method and apparatus for pressurized intraluminal drug delivery |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5569197A (en) | 1994-12-21 | 1996-10-29 | Schneider (Usa) Inc | Drug delivery guidewire |
| WO1996021224A1 (en) | 1994-12-29 | 1996-07-11 | Sony Corporation | Disk cartridge |
| US6759042B2 (en) | 1999-06-04 | 2004-07-06 | Thrombotech Ltd | Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent |
| US6867177B2 (en) | 1999-08-13 | 2005-03-15 | The Trustees Of Columbia University In The City Of New York | CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders |
| US6699230B2 (en) | 2000-05-10 | 2004-03-02 | Minnesota Medical Physics, Llc | Apparatus and method for out-of-hospital thrombolytic therapy |
| GB0025473D0 (en) | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
| CN1142278C (zh) | 2001-04-04 | 2004-03-17 | 刘建宁 | 一类能被尿激酶或自身激活的尿激酶原变体及其编码基因、制备方法和用途 |
| US7084118B2 (en) * | 2002-02-22 | 2006-08-01 | Genentech, Inc. | Combination treatment with t-PA variant and low molecular weight heparin |
| US7070958B2 (en) | 2003-04-18 | 2006-07-04 | Thrombolytic Science, Inc. | Methods of making pro-urokinase mutants |
| CA2426115A1 (en) | 2003-04-18 | 2004-10-18 | Victor Gurewich | Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
| JP2006241109A (ja) | 2005-03-04 | 2006-09-14 | Paion Deutschland Gmbh | ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質 |
| US8071532B2 (en) * | 2005-12-21 | 2011-12-06 | Pharming Intellectual Property B.V. | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury |
| US20070298024A1 (en) * | 2006-06-22 | 2007-12-27 | Thrombolytic Science, Inc. | C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis |
| US20090010916A1 (en) * | 2006-06-22 | 2009-01-08 | Victor Gurewich | C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| CN101015686B (zh) * | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
| CN101549150A (zh) * | 2008-03-31 | 2009-10-07 | 刘建宁 | 尿激酶原及尿激酶原变体在急性心肌梗塞易化经皮冠状动脉介入中的应用 |
| CN107073292B (zh) | 2014-11-03 | 2021-07-02 | 溶栓科学有限责任公司 | 用于安全和有效的溶栓的方法和组合物 |
-
2015
- 2015-11-03 CN CN201580058489.0A patent/CN107073292B/zh active Active
- 2015-11-03 US US15/523,900 patent/US11213574B2/en active Active
- 2015-11-03 ES ES15856204T patent/ES2788697T3/es active Active
- 2015-11-03 DK DK15856204.1T patent/DK3215221T3/da active
- 2015-11-03 JP JP2017543288A patent/JP6826040B2/ja active Active
- 2015-11-03 EP EP20158876.1A patent/EP3708226A1/en not_active Withdrawn
- 2015-11-03 EA EA201790969A patent/EA035358B1/ru unknown
- 2015-11-03 CA CA2966332A patent/CA2966332C/en active Active
- 2015-11-03 WO PCT/US2015/058878 patent/WO2016073514A2/en not_active Ceased
- 2015-11-03 EP EP15856204.1A patent/EP3215221B1/en active Active
- 2015-11-03 MX MX2017005793A patent/MX383561B/es unknown
-
2021
- 2021-12-30 US US17/566,077 patent/US12590301B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar | An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy | |
| JP2019529457A5 (enExample) | ||
| JP2007332155A5 (enExample) | ||
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| JP2018138578A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| WO2017100700A3 (en) | Peptides for renal therapy | |
| Ndrepepa | Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI | |
| JP2015535237A5 (enExample) | ||
| Muroya et al. | Deficiency in the formation of 20-hydroxyeicosatetraenoic acid enhances renal ischemia-reperfusion injury | |
| RU2015119603A (ru) | Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc | |
| Hermanns et al. | Anesthesia considerations in infective endocarditis | |
| Saini et al. | Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia | |
| JP2012220493A5 (enExample) | ||
| JP2016534062A5 (enExample) | ||
| FI4000628T3 (fi) | Koostumus ja menetelmä vankomysiinin oraaliselle nesteelle | |
| Makwana et al. | Antifibrinolytics in liver surgery | |
| JP6826040B2 (ja) | 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物 | |
| Kim et al. | Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke | |
| Boden et al. | ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy | |
| Vande Vusse et al. | Prohemostatic therapy: the rise and fall of aprotinin | |
| Dasbiswas et al. | Overview of reteplase, A novel thrombolytic agent in Indian context | |
| MX2017013384A (es) | Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. | |
| Omčikus et al. | ORAL ANTICOAGULANTS IN THE TREATMENT OF PULMONARY THROMBOEMBOLISM | |
| Mozafar et al. | Effects of clopidogrel on longevity of permanent double-lumen catheter patency in dialysis patients: A single-blind placebo-controlled clinical trial |